|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
|
US11982673B2
(en)
|
2014-03-05 |
2024-05-14 |
Autolus Limited |
Methods
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
DK3143134T3
(da)
|
2014-05-15 |
2021-01-04 |
Nat Univ Singapore |
Modificerede, naturlige dræberceller og anvendelser deraf
|
|
GB201415347D0
(en)
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
GB201501936D0
(en)
*
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
|
PL3298033T5
(pl)
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
GB201610512D0
(en)
|
2016-06-16 |
2016-08-03 |
Autolus Ltd |
Chimeric antigen receptor
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018067993A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
BR112019019917A2
(pt)
|
2017-03-27 |
2020-04-22 |
Nat Univ Singapore |
receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
|
|
CA3056591A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
WO2018176144A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Sunnybrook Research Institute |
Engineered t-cell modulating molecules and methods of using same
|
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
US20210130775A1
(en)
*
|
2017-08-02 |
2021-05-06 |
Autolus Limited |
Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
|
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
|
GB201801831D0
(en)
*
|
2018-02-05 |
2018-03-21 |
Autolus Ltd |
Chimeric receptor
|
|
EP3749685A4
(en)
|
2018-02-09 |
2021-12-22 |
National University of Singapore |
ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
MX2020012028A
(es)
|
2018-05-11 |
2021-03-29 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer.
|
|
GB201807870D0
(en)
|
2018-05-15 |
2018-06-27 |
Autolus Ltd |
A CD79-specific chimeric antigen receptor
|
|
WO2019220109A1
(en)
|
2018-05-15 |
2019-11-21 |
Autolus Limited |
Chimeric antigen receptor
|
|
EP3836944A4
(en)
*
|
2018-08-16 |
2022-05-11 |
Memorial Sloan Kettering Cancer Center |
LEUCINE ZIPPER BASED COMPOSITIONS AND METHODS OF USE
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
CN109265550B
(zh)
*
|
2018-09-25 |
2020-09-15 |
华东师范大学 |
Bcma抗体、嵌合抗原受体和药物
|
|
IL281428B2
(en)
|
2018-09-27 |
2024-10-01 |
Autolus Ltd |
Chimeric antigen receptor
|
|
WO2020070290A1
(en)
*
|
2018-10-05 |
2020-04-09 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3860642A1
(en)
*
|
2018-10-05 |
2021-08-11 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
GB201817822D0
(en)
|
2018-10-31 |
2018-12-19 |
Autolus Ltd |
Binding domain
|
|
CA3120563A1
(en)
|
2018-11-26 |
2020-06-04 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
JP7812549B2
(ja)
*
|
2019-02-21 |
2026-02-10 |
アーベル リミテッド |
人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
|
CA3132587A1
(en)
|
2019-03-21 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
MX2021013359A
(es)
|
2019-04-30 |
2022-01-31 |
Crispr Therapeutics Ag |
Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
|
|
GB201919017D0
(en)
|
2019-12-20 |
2020-02-05 |
Autolus Ltd |
Cell
|
|
CN111234033B
(zh)
*
|
2020-01-21 |
2021-05-11 |
南京北恒生物科技有限公司 |
多链嵌合抗原受体及其用途
|
|
GB202004263D0
(en)
|
2020-03-24 |
2020-05-06 |
Autolus Ltd |
Antibody conjugate
|
|
GB202005216D0
(en)
|
2020-04-08 |
2020-05-20 |
Autolus Ltd |
Cell
|
|
GB202006820D0
(en)
|
2020-05-07 |
2020-06-24 |
Autolus Ltd |
Cell
|
|
GB202017649D0
(en)
|
2020-11-09 |
2020-12-23 |
Autolus Ltd |
Polypeptide
|
|
US12144827B2
(en)
|
2021-02-25 |
2024-11-19 |
Lyell Immunopharma, Inc. |
ROR1 targeting chimeric antigen receptor
|
|
WO2022204326A1
(en)
*
|
2021-03-24 |
2022-09-29 |
The Regents Of The University Of California |
Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
|
|
GB202115329D0
(en)
*
|
2021-10-25 |
2021-12-08 |
Autolus Ltd |
Chimeric cytokine receptor
|
|
WO2024019961A1
(en)
*
|
2022-07-18 |
2024-01-25 |
Cargo Therapeutics, Inc. |
Cd2 recruiting chimeric antigen receptors and fusion proteins
|
|
WO2025160324A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|